BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 21884024)

  • 21. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
    Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
    Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.
    Kitamura S; Maeda K; Wang Y; Sugiyama Y
    Drug Metab Dispos; 2008 Oct; 36(10):2014-23. PubMed ID: 18617601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Hepatic and Intestinal Efflux Transport of Statins.
    Deng F; Tuomi SK; Neuvonen M; Hirvensalo P; Kulju S; Wenzel C; Oswald S; Filppula AM; Niemi M
    Drug Metab Dispos; 2021 Sep; 49(9):750-759. PubMed ID: 34162690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins.
    Salphati L; Chu X; Chen L; Prasad B; Dallas S; Evers R; Mamaril-Fishman D; Geier EG; Kehler J; Kunta J; Mezler M; Laplanche L; Pang J; Rode A; Soars MG; Unadkat JD; van Waterschoot RA; Yabut J; Schinkel AH; Scheer N
    Drug Metab Dispos; 2014 Aug; 42(8):1301-13. PubMed ID: 24855184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
    Ebner T; Ishiguro N; Taub ME
    J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data.
    Kunze A; Huwyler J; Camenisch G; Poller B
    Drug Metab Dispos; 2014 Sep; 42(9):1514-21. PubMed ID: 24989890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins.
    Sharma P; Butters CJ; Smith V; Elsby R; Surry D
    Eur J Pharm Sci; 2012 Aug; 47(1):244-55. PubMed ID: 22538052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport.
    Kindla J; Müller F; Mieth M; Fromm MF; König J
    Drug Metab Dispos; 2011 Jun; 39(6):1047-53. PubMed ID: 21389119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions.
    Izumi S; Nozaki Y; Maeda K; Komori T; Takenaka O; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2015 Feb; 43(2):235-47. PubMed ID: 25414411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1.
    Elsby R; Hilgendorf C; Fenner K
    Clin Pharmacol Ther; 2012 Nov; 92(5):584-98. PubMed ID: 23047648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin.
    Hirano M; Maeda K; Matsushima S; Nozaki Y; Kusuhara H; Sugiyama Y
    Mol Pharmacol; 2005 Sep; 68(3):800-7. PubMed ID: 15955871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration.
    Gupta A; Harris JJ; Lin J; Bulgarelli JP; Birmingham BK; Grimm SW
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5986-94. PubMed ID: 27458210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.
    Matsushima S; Maeda K; Kondo C; Hirano M; Sasaki M; Suzuki H; Sugiyama Y
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1059-67. PubMed ID: 15901800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.
    Kivistö KT; Niemi M
    Pharm Res; 2007 Feb; 24(2):239-47. PubMed ID: 17177112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BacMam recombinant baculovirus in transporter expression: a study of BCRP and OATP1B1.
    Hassan NJ; Pountney DJ; Ellis C; Mossakowska DE
    Protein Expr Purif; 2006 Jun; 47(2):591-8. PubMed ID: 16481201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity.
    Huh Y; Plotka A; Wei H; Kaplan J; Raha N; Towner J; Purohit VS; Dowty ME; Wolk R; Vourvahis M; King-Ahmad A; Mathialagan S; West MA; Lazzaro S; Ryu S; Rodrigues AD
    Pharm Res; 2023 Nov; 40(11):2639-2651. PubMed ID: 37561322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.
    Oostendorp RL; van de Steeg E; van der Kruijssen CM; Beijnen JH; Kenworthy KE; Schinkel AH; Schellens JH
    Drug Metab Dispos; 2009 Apr; 37(4):917-23. PubMed ID: 19139163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
    Neuvonen PJ
    Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacogenomics: inter-ethnic and intra-ethnic differences in pharmacokinetic and pharmacodynamic profiles of clinically relevant drugs].
    Ieiri I; Higuchi S
    Yakugaku Zasshi; 2009 Feb; 129(2):231-5. PubMed ID: 19182452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous Assessment of Transporter-Mediated Drug-Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey.
    Kosa RE; Lazzaro S; Bi YA; Tierney B; Gates D; Modi S; Costales C; Rodrigues AD; Tremaine LM; Varma MV
    Drug Metab Dispos; 2018 Aug; 46(8):1179-1189. PubMed ID: 29880631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.